Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon-Like Peptide 1 Agonist: A Case Report. [PDF]
Respirol Case RepKumar S +4 more
europepmc +1 more source
Glucagon-like peptide-1 agonists' effects on glycemic control, weight loss, and beta cells function in type 1 diabetes. [PDF]
Front Endocrinol (Lausanne)Mirghani HO, Albishi L, Alblewi SM.
europepmc +1 more source
Impact of Glucagon-Like Peptide-1 Receptor Agonists on Knee Arthroplasty Outcomes. [PDF]
Indian J OrthopZaffar H, Imran MA, Rushd F.
europepmc +1 more source
History of glucagon-like peptide-1 receptor agonists
Pharmacological ResearchRadwan Darwish +2 more
doaj +1 more source
Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use. [PDF]
Diabetes Obes MetabVilsbøll T +8 more
europepmc +1 more source
Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study. [PDF]
Health Aff SchMattingly TJ, Duru EE, Conti RM.
europepmc +1 more source
Glucagon-Like Peptide-1 Receptor Agonists for Arthritis and Osteoarthritis. [PDF]
CureusNashwan AJ.
europepmc +1 more source
Glucagon-Like Peptide-1 Receptor Agonists in Chronic Kidney Disease: Mechanisms and Clinical Perspectives. [PDF]
Kidney MedMeier M +6 more
europepmc +1 more source
Thyroid Cancer Risk in Patients With Type 2 Diabetes Taking Glucagon-Like Peptide 1 Receptor Agonists. [PDF]
OTO OpenSciscent BY +5 more
europepmc +1 more source
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review. [PDF]
CureusGraczyk NA, Bisschops J.
europepmc +1 more source